100 - New Antimicrobials in the Pipeline

Friday, October 18, 2024

8:00 AM – 9:00 AM US PT

Location: Petree C

All relevant financial relationships have been mitigated.

CME Credits: Maximum of 0 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 0 hours of MOC Credit
CNE Credits: Maximum of 0 hours of ANCC Credit
ACPE Credits: ACPE 0 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 0 of PACE contact hours
CE Broker: Maximum of 0 CE broker credit hours

Moderator(s)

Lisa Dumkow, Pharm D., BCIDP (she/her/hers)

Antimicrobial Stewardship Clinical Pharmacist
Trinity Health Grand Rapids
Grand Rapids, Michigan, United States
Cesar Arias, MD, MSc, PhD (he/him/his)

Professor and Chief
Houston Methodist and Weill Cornell Medical College
Houston, TX, United States

Disclosure(s):

Lisa E. Dumkow, Pharm D., BCIDP: No financial relationships to disclose

Cesar A. Arias, MD, MSc, PhD: UpToDate, Inc.: Royalties

Presentations:

8:00 AM – 9:00 AM US PT

Zoliflodacin: Addressing a growing global threat through a novel public-private development partnership
Speaker: David Altarac, MD – Innoviva Speciality Therapeutics
8:00 AM – 9:00 AM US PT

Clarametyx Biosciences, CMTX-101
Speaker: Steve St. Onge, PharmD MBA – Clarametyx
8:00 AM – 9:00 AM US PT

AIC468 - a first-in-class antiviral antisense oligonucleotide for the treatment of BKV infection in kidney transplant recipients
Speaker: Tamara Pfaff, DVM, – AiCuris anti-infective Cures AG
8:00 AM – 9:00 AM US PT

Fosmanogepix, Basilea Pharmaceutica International Ltd, Allschwil (Switzerland)
Speaker: Marc Engelhardt, MD (he/him/his) – Basilea Pharmaceutica International Ltd., Allschwil, Switzerland